Advertisement

Radiation Dose–Volume Effects in the Stomach and Small Bowel

      Published data suggest that the risk of moderately severe (≥Grade 3) radiation-induced acute small-bowel toxicity can be predicted with a threshold model whereby for a given dose level, D, if the volume receiving that dose or greater (VD) exceeds a threshold quantity, the risk of toxicity escalates. Estimates of VD depend on the means of structure segmenting (e.g., V15 = 120 cc if individual bowel loops are outlined or V45 = 195 cc if entire peritoneal potential space of bowel is outlined). A similar predictive model of acute toxicity is not available for stomach. Late small-bowel/stomach toxicity is likely related to maximum dose and/or volume threshold parameters qualitatively similar to those related to acute toxicity risk. Concurrent chemotherapy has been associated with a higher risk of acute toxicity, and a history of abdominal surgery has been associated with a higher risk of late toxicity.
      To read this article in full you will need to make a payment
      ASTRO Member Login
      ASTRO Members, full access to the journal is a member benefit. Use your society credentials to access all journal content and features.
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Coia L.R.
        • Myerson R.J.
        • Tepper J.E.
        Late effects of radiation therapy on the gastrointestinal tract.
        Int J Radiat Oncol Biol Phys. 1995; 31: 1213-1236
        • Vistad I.
        • Kristensen G.B.
        • Fosså S.D.
        • et al.
        Intestinal malabsorption in long-term survivors of cervical cancer treated with radiotherapy.
        Int J Radiat Oncol Biol Phys. 2009; 73: 1141-1147
        • Acker J.C.
        • Marks L.B.
        The lack of impact of pelvic irradiation on small bowel mobility: Implications for radiotherapy treatment planning.
        Int J Radiat Oncol Biol Phys. 1995; 32: 1473-1475
        • Martin J.
        • Fitzpatrick K.
        • Horan G.
        • et al.
        Treatment with a belly-board device significantly reduces the volume of small bowel irradiated and results in low acute toxicity in adjuvant radiotherapy for gynecologic cancer: Results of a prospective study.
        Radiother Oncol. 2005; 74: 267-274
        • Emami B.
        • Lyman J.
        • Brown A.
        • et al.
        Tolerance of normal tissue to therapeutic irradiation.
        Int J Radiat Oncol Biol Phys. 1991; 21: 109-122
        • Ishikura S.
        • Tobinai K.
        • Ohtsu A.
        • et al.
        Japanese multicenter phase II study of CHOP followed by radiotherapy in stage I–II, diffuse large B-cell lymphoma of the stomach.
        Cancer Sci. 2005; 96: 349-352
        • Moertel C.G.
        • Frytak S.
        • Hahn R.G.
        • et al.
        Therapy of locally unresectable pancreatic carcinoma: A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group.
        Cancer. 1981; 48: 1705-1710
        • Sykes A.J.
        • Kiltie A.E.
        • Stewart A.L.
        Ondansetron versus a chlorpromazine and dexamethasone combination for the prevention of nausea and vomiting: A prospective, randomised study to assess efficacy, cost effectiveness and quality of life following single-fraction radiotherapy.
        Support Care Cancer. 1997; 5: 500-503
        • Wong R.K.
        • Paul N.
        • Ding K.
        • et al.
        5-Hydroxytryptamine-3 receptor antagonist with or without short-course dexamethasone in the prophylaxis of radiation induced emesis: A placebo-controlled randomized trial of the National Cancer Institute of Canada Clinical Trials Group (SC19).
        J Clin Oncol. 2006; 24: 3458-3464
        • Brick I.B.
        Effects of million volt irradiation on the gastrointestinal tract.
        Arch Intern Med. 1955; 96: 26-31
        • Cosset J.M.
        • Henry-Amar M.
        • Burgers J.M.
        • et al.
        Late radiation injuries of the gastrointestinal tract in the H2 and H5 EORTC Hodgkin's disease trials: Emphasis on the role of exploratory laparotomy and fractionation.
        Radiother Oncol. 1988; 13: 61-68
        • Goldstein H.M.
        • Rogers L.F.
        • Fletcher G.H.
        • Dodd G.D.
        Radiological manifestations of radiation-induced injury to the normal upper gastrointestinal tract.
        Radiology. 1975; 117: 135-140
        • Cohen S.J.
        • Dobelbower Jr., R.
        • Lipsitz S.
        • et al.
        A randomized phase III study of radiotherapy alone or with 5-fluorouracil and mitomycin-C in patients with locally advanced adenocarcinoma of the pancreas: Eastern Cooperative Oncology Group study E8282.
        Int J Radiat Oncol Biol Phys. 2005; 62: 1345-1350
        • Talamonti M.S.
        • Catalano P.J.
        • Vaughn D.J.
        • et al.
        Eastern Cooperative Oncology Group Phase I trial of protracted venous infusion fluorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer: A regimen with unexpected early toxicity.
        J Clin Oncol. 2000; 18: 3384-3389
        • Li C.P.
        • Chao Y.
        • Chi K.H.
        • et al.
        Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer: Gemcitabine versus 5-fluorouracil, a randomized controlled study.
        Int J Radiat Oncol Biol Phys. 2003; 57: 98-104
        • Loehrer P.
        • Powell M.E.
        • Cardenes H.R.
        • et al.
        A randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer.
        J Clin Oncol. 2008; (abstract 4506): 26
        • Murphy J.D.
        • Adusumilli S.
        • Griffith K.A.
        • et al.
        Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer.
        Int J Rad Oncol Biol Phys. 2007; 68: 801-808
        • Baglan K.L.
        • Frazier R.C.
        • Yan D.
        • et al.
        The dose-volume relationship of acute small bowel toxicity from concurrent 5-FU-based chemotherapy and radiation therapy for rectal cancer.
        Int J Radiat Oncol Biol Phys. 2002; 52: 176-183
        • Roeske J.C.
        • Bonta D.
        • Mell L.K.
        • et al.
        A dosimetric analysis of acute gastrointestinal toxicity in women receiving intensity-modulated whole-pelvic radiation therapy.
        Radiother Oncol. 2003; 69: 201-207
        • Tho L.M.
        • Glegg M.
        • Paterson J.
        • et al.
        Acute small bowel toxicity and preoperative chemoradiotherapy for rectal cancer: Investigating dose-volume relationships and role for inverse planning.
        Int J Radiat Oncol Biol Phys. 2006; 66: 505-513
        • Huang E.Y.
        • Sung C.C.
        • Ko S.F.
        • et al.
        The different volume effects of small-bowel toxicity during pelvic irradiation between gynecologic patients with and without abdominal surgery: A prospective study with computed tomography-based dosimetry.
        Int J Radiat Oncol Biol Phys. 2007; 69: 732-739
        • Robertson J.M.
        • Lockman D.
        • Yan D.
        • et al.
        The dose-volume relationship of small bowel irradiation and acute grade 3 diarrhea during chemoradiotherapy for rectal cancer.
        Int J Radiat Oncol Biol Phys. 2008; 70: 413-418
        • Gunnlaugsson A.
        • Kjellen E.
        • Nilsson P.
        • et al.
        Dose-volume relationships between enteritis and irradiated bowel volumes during 5-fluorouracil and oxaliplatin based chemoradiotherapy in locally advanced rectal cancer.
        Acta Oncol. 2007; 46: 937-944
        • Keys H.M.
        • Bundy B.N.
        • Stehman F.B.
        • et al.
        Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma.
        N Engl J Med. 1999; 340: 1154-1161
        • Macdonald J.S.
        • Smalley S.R.
        • Benedetti J.
        • et al.
        Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
        N Engl J Med. 2001; 345: 725-730
        • Bosset J.F.
        • Collette L.
        • Calais G.
        • et al.
        Chemotherapy with preoperative radiotherapy in rectal cancer.
        N Engl J Med. 2006; 355: 1114-1123
        • Mak A.C.
        • Rich T.A.
        • Schultheiss T.E.
        • et al.
        Late complications of postoperative radiation therapy for cancer of the rectum and rectosigmoid.
        Int J Radiat Oncol Biol Phys. 1994; 28: 597-603
        • Hamilton C.R.
        • Horwich A.
        • Bliss J.M.
        • et al.
        Gastrointestinal morbidity of adjuvant radiotherapy in stage I malignant teratoma of the testis.
        Radiother Oncol. 1987; 10: 85-90
        • Frykholm G.J.
        • Glimelius B.
        • Pahlman L.
        Preoperative or postoperative irradiation in adenocarcinoma of the rectum: Final treatment results of a randomized trial and an evaluation of late secondary effects.
        Dis Colon Rectum. 1993; 36: 564-572
        • Peeters K.C.
        • van de Velde C.J.
        • Leer J.W.
        • et al.
        Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: Increased bowel dysfunction in irradiated patients—a Dutch colorectal cancer group study.
        J Clin Oncol. 2005; 23: 6199-6206
        • Peeters K.C.
        • Marijnen C.A.
        • Nagtegaal I.D.
        • et al.
        The TME trial after a median follow-up of 6 years: Increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma.
        Ann Surg. 2007; 246: 693-701
        • Folkesson J.
        • Birgisson H.
        • Pahlman L.
        • et al.
        Swedish Rectal Cancer Trial: Long lasting benefits from radiotherapy on survival and local recurrence rate.
        J Clin Oncol. 2005; 23: 5644-5650
        • Birgisson H.
        • Pahlman L.
        • Gunnarsson U.
        • et al.
        Late gastrointestinal disorders after rectal cancer surgery with and without preoperative radiation therapy.
        Br J Surg. 2008; 95: 206-213
        • Bujko K.
        • Nowacki M.P.
        • Nasierowska-Guttmejer A.
        • et al.
        Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer.
        Br J Surg. 2006; 93: 1215-1223
        • Sauer R.
        • Becker H.
        • Hohenberger W.
        • et al.
        Preoperative versus postoperative chemoradiotherapy for rectal cancer.
        N Engl J Med. 2004; 351: 1731-1740
        • Pan C.C.
        • Dawson L.A.
        • McGinn C.J.
        • et al.
        Analysis of radiation-induced gastric and duodenal bleeds using the Lyman-Kutcher-Burman model.
        Int J Radiat Oncol Biol Phys. 2003; 57: S217-S218
        • Chen M.F.
        • Tseng C.J.
        • Tseng C.C.
        • et al.
        Clinical outcome in posthysterectomy cervical cancer patients treated with concurrent Cisplatin and intensity-modulated pelvic radiotherapy: Comparison with conventional radiotherapy.
        Int J Radiat Oncol Biol Phys. 2007; 67: 1438-1444
        • Letschert J.G.
        • Lebesque J.V.
        • de Boer R.W.
        • et al.
        Dose-volume correlation in radiation-related late small-bowel complications: A clinical study.
        Radiother Oncol. 1990; 18: 307-320
        • Hoyer M.
        • Roed H.
        • Traberg Hansen A.
        • et al.
        Phase II study on stereotactic body radiotherapy of olorectal metastases.
        Acta Oncol. 2006; 45: 823-830
        • Koong A.C.
        • Christofferson E.
        • Le Q.T.
        • et al.
        Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer.
        Int J Radiat Oncol Biol Phys. 2005; 63: 320-323
        • Schellenberg D.
        • Goodman K.A.
        • Lee F.
        • et al.
        Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer.
        Int J Radiat Oncol Biol Phys. 2008; 72: 678-686
        • Chang D.T.
        • Schellenberg D.
        • Shen J.
        • et al.
        Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas.
        Cancer. 2009; 115: 665-672
        • Hoyer M.
        • Roed H.
        • Sengelov L.
        • et al.
        Phase II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma.
        Radiother Oncol. 2005; 76: 48-53
        • Streitparth F.
        • Pech M.
        • Böhmig M.
        • et al.
        In vivo assessment of the gastric mucosal tolerance dose after single fraction, small volume irradiation of liver malignancies by computed tomography-guided, high-dose-rate brachytherapy.
        Int J Radiat Oncol Biol Phys. 2006; 65: 1479-1486

      Comments

      Commenting Guidelines

      To submit a comment for a journal article, please use the space above and note the following:

      • We will review submitted comments as soon as possible, striving for within two business days.
      • This forum is intended for constructive dialogue. Comments that are commercial or promotional in nature, pertain to specific medical cases, are not relevant to the article for which they have been submitted, or are otherwise inappropriate will not be posted.
      • We require that commenters identify themselves with names and affiliations.
      • Comments must be in compliance with our Terms & Conditions.
      • Comments are not peer-reviewed.